arrow
D

David J. Noble

University of Edinburgh
H指数:14
被引数:768

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Erratum to “Identifying the optimal time point for adaptive re-planning in prostate cancer radiotherapy to minimise rectal toxicity using normal tissue imaging biomarkers” [Phys. Imaging Radiat. Oncol. 36 (2025) 100850]

勘误:“利用正常组织成像生物标志物识别前列腺癌放疗中自适应再规划以最小化直肠毒性的最佳时间点”[Phys. Imaging Radiat. Oncol. 36 (2025) 100850]

2026-08-260
OAAI
Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare data

PROSECCA研究方案:利用人工智能和电子人口基线医疗数据预测放射治疗效果的新方法

2026-02-020
OA
Multidisciplinary evidence-based consensus statements on salvage surgery for recurrent head and neck cancer (International Centre for Recurrent Head and Neck Cancer)

多学科循证共识声明:复发性头颈癌的挽救性手术(International Centre for Recurrent Head and Neck Cancer)

2025-09-011
PRE
Prognostic Implications of HPV Cell-Free DNA Serial Testing During Follow-Up of p16 Positive Oropharyngeal Squamous Cell Carcinoma After Curative-Intent Treatment

p16阳性口咽鳞状细胞癌在根治性治疗后的随访期间,人乳头瘤病毒细胞游离DNA系列检测的预后意义

2025-05-010
OAAI
The UK Divide: Does Having a Pembrolizumab- Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab- Chemotherapy Combination in Scotland

英国的分歧: 在头颈癌中使用Pembrolizumab化疗方案是否重要?苏格兰一线姑息性Pembrolizumab单药治疗和Pembrolizumab-化疗联合治疗的真实世界经验

2024-05-012
OAAI
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK

在英国使用pembrolizumab单药治疗头颈部鳞状细胞癌 (HNSCC)

2024-04-290
OA